Biopharmaceutical News and Research

RSS

InDevR and Sino Biological team up to deliver multiplexed analytical solutions for mRNA vaccine and cell & gene therapy

InDevR, Inc., a leader in analytical solutions for vaccine in-process and quality control testing, and Sino Biological, Inc., a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext specializing in biological research reagents and related technical contract research services, today announced a new partnership to speed development of multiplexed assays for a broad range of vaccine, mRNA therapies and cell and gene therapy applications.

From Sino Biological Inc. 7 Jun 2024

Novel small molecule oral antiviral could be a game-changer in the fight against future pandemics

Obeldesivir (GS-5245), a novel investigational small molecule oral antiviral, represents a new tool in the ongoing effort to prepare for future pandemics.

4 Jun 2024

DefiniGEN and Atelerix collaborate to ship in vitro cell models internationally without the need for freezing or cryopreservation

DefiniGEN Ltd., and Atelerix Ltd., today announced they have successfully shipped in vitro liver models from the UK to a top tier pharma customer in the US. The agreement between the companies combines DefiniGEN’s mechanistically relevant iPSC hepatocytes (Opti-Heps) with Atelerix's hydrogel preservation technology, which prevents loss of function and enables even sensitive samples to remain stable at ambient temperatures for up to two weeks.

From Defini Gen 3 Jun 2024

UMSOM receives $3.96 million grant for maternal vaccine against neonatal sepsis

University of Maryland School of Medicine (UMSOM) researchers at the Center for Vaccine Development and Global Health (CVD) have been awarded $3.96 million to develop a maternal vaccine that prevents sepsis caused by Klebsiella pneumoniae in newborns and infants.

23 May 2024

Refeyn strengthens capability with new US Headquarters in Boston area

Refeyn, the pioneer of mass photometry technology, is continuing to strengthen the deployment of its unique bioanalytical tools with the planned Grand Opening of its new US Headquarters and Customer Interaction Center, in conjunction with the third annual Mass Photometry Summit 2024. Following the summit, highlighting the very latest advances in mass photometry, to be held in the Boston area on May 22, Refeyn will officially open its new 10,000 sq. ft. HQ in the heart of Waltham’s Biotech Hub in Greater Boston, Massachusetts, on May 23.

From Refeyn 23 May 2024

CYTENA unveils revolutionary C.WASH PLUS: The future of microplate washing and dispensing

CYTENA, a BICO company, proudly announces the launch of C.WASH PLUS, a cutting-edge microplate washer and dispenser. Engineered for high throughput and automation, the C.WASH PLUS delivers unparalleled consistency and precise dispensing for immune and cell-based assays.

From CYTENA GmbH 22 May 2024

PhoreMost introduces GlueSEEKER platform for discovery of molecular glue degraders

PhoreMost Ltd., a leading UK biopharmaceutical company unlocking the next generation of drug targets, today announced the introduction of GlueSEEKER™.

From PhoreMost 22 May 2024

RedShiftBio launches Aurora TX: Revolutionizing RNA and protein analysis with ultra-sensitive microfluidic modulation spectroscopy and thermal ramping capability

RedShiftBio, a leader in innovative biophysical characterization and bioprocess analytical solutions, proudly announces the launch of Aurora TX at The Protein & Antibody Engineering Summit (PEGS), kicking off on May 13, 2024, in Boston, MA. Aurora TX is the company's latest, most advanced instrument featuring ground-breaking MMS technology, and sets a new standard in biomolecular analysis by providing ultra-sensitive, ultra-precise measurements of biomolecule structure and stability, now enhanced with the addition of thermal ramping capability.

From RedShiftBio 16 May 2024

ArgusEye closes €2.8 million funding to accelerate bioprocessing

ArgusEye, a provider of innovative sensor solutions for real-time monitoring of biological systems, today announced the close of its funding, raising €2.8 million EUR (~£2.4 million GBP) bringing the total raised by the Company to €3.45 million EUR (~£3 million GPB).

From ArgusEye AB 13 May 2024

UT Health San Antonio leads effort for developing oral vaccine against chlamydia

The study of a novel oral vaccine that could protect against chlamydia infection has been awarded approximately $11 million in National Institutes of Health funding over five years through a cooperative agreements research project grant, known as a U01 grant.

9 May 2024

Gyros Protein Technologies introduces Gyrolab Generic Rodent ADA Kit Reagents to support preclinical immunogenicity assessment

...

From Gyros Protein Technologies AB 3 May 2024

Sphere Fluidics appoints Dale Levitzke as Chief Executive Officer

...

From Sphere Fluidics 2 May 2024

CN Bio raises $21 million USD in first close of Series B investment round

Bayland Capital and founding shareholder, CN Innovations Holdings Ltd, to invest $10 M and $5.5 M, respectively. Investment will expand product development and scaling of the organization to meet increased demand for Organ-on-a-Chip (OOC) solutions.

23 Apr 2024

MD Anderson and CureVac collaborate on mRNA-based cancer vaccines

The University of Texas MD Anderson Cancer Center and CureVac N.V. today announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.

16 Apr 2024

$Hip fracture survival rates in seniors worse than many cancers, study shows$

Biopharmaceutical News and Research

InDevR and Sino Biological team up to deliver multiplexed analytical solutions for mRNA vaccine and cell & gene therapy

Novel small molecule oral antiviral could be a game-changer in the fight against future pandemics

DefiniGEN and Atelerix collaborate to ship in vitro cell models internationally without the need for freezing or cryopreservation

UMSOM receives $3.96 million grant for maternal vaccine against neonatal sepsis

Refeyn strengthens capability with new US Headquarters in Boston area

CYTENA unveils revolutionary C.WASH PLUS: The future of microplate washing and dispensing

PhoreMost introduces GlueSEEKER platform for discovery of molecular glue degraders

RedShiftBio launches Aurora TX: Revolutionizing RNA and protein analysis with ultra-sensitive microfluidic modulation spectroscopy and thermal ramping capability

ArgusEye closes €2.8 million funding to accelerate bioprocessing

UT Health San Antonio leads effort for developing oral vaccine against chlamydia

Gyros Protein Technologies introduces Gyrolab Generic Rodent ADA Kit Reagents to support preclinical immunogenicity assessment

Sphere Fluidics appoints Dale Levitzke as Chief Executive Officer

CN Bio raises $21 million USD in first close of Series B investment round

MD Anderson and CureVac collaborate on mRNA-based cancer vaccines

Hip fracture survival rates in seniors worse than many cancers, study shows

New technique reveals insights into gut cell dynamics during inflammation

Ubiquigent and Debiopharm enter agreement to support USP1 inhibitor programme for Debio 0432

ArgusEye introduces AugaOne to accelerate downstream bioprocess development

Precision unveiled: Exploring the cutting-edge of analytical weighing with Cubis® II ultra-high resolution balances

Biden is right. The US generally pays double that of other countries for Rx drugs.

Pittcon Highlights: Pharmaceutical & Biologic eBook

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Latest News